Vol. 3 No. 5 (2023)
Reimbursement Reviews

Pegcetacoplan (Empaveli)

Published May 18, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pegcetacoplan (Empaveli), 54 mg/mL, solution, subcutaneous infusion.
  • Indication: For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria who have an inadequate response to, or are intolerant of, a C5 inhibitor.